Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) News

Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO)

Today's Latest Price: $58.63 USD

0.22 (-0.37%)

Updated Oct 30 7:00pm

Add TARO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter TARO News Items

TARO News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest TARO News From Around the Web

Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Taro Pharmaceutical launches generic Deferiprone in U.S.

Taro Pharmaceutical ([[TARO]] -0.5%) has announced the launch of deferiprone, a generic version of Chiesi's Ferriprox, an iron chelator indicated for transfusional iron overload due to thalassemia syndromes, when current chelation therapy is not sufficient.The company will team up with BioPlus Specialty Pharmacy for distribution of deferiprone tablets at launch....

Seeking Alpha | September 28, 2020

Legal woes, decline in sales hurt Sun Pharma: Q1 key takeaways

NEW DELHI: Hurt by one-time loss, leading drugmaker Sun Pharma reported a surprising loss during the June quarter while sales declined in all regions of the world the company operates in.However, the management hailed the company's performance. They said it has done well given the challenges it faced and managed to hold its market share in India and the US.How much did the company earn?Sun Pharma reported a loss of Rs 1,655.60 crore in the quarter, sharply lower from the expectation as it recognised an exceptional item. The company’s revenues from operations also fell to Rs 7,467.19 crore, from Rs 8,259.30 crore a year ago. EBITDA was at Rs 1,725 crores, with resulting EBITDA margin of 23.1 per cent.What is that exceptional item?The company reported a one-time loss of Rs 3,633.33 crore ...

Economic Times India | July 31, 2020

Sun Pharma's Subsidiary Taro Pharma To Acquire Canada's Aquinox Pharma

On Wednesday, in a stock exchange filing, Sun Pharma said that a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for $8.2 million (approx Rs 61.35 crore) in cash. Aquinox Pharmaceuticals is a corporation organised

Goodreturns | July 29, 2020

Taro Pharma to acquire Canada’s Aquinox Pharmaceutical for USD 8.2 million | Business

Drug major Sun Pharma on Wednesday said a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for USD 8.2 million (approx Rs 61.35 crore) in cash. 100 per cent shareholding, constituting equity shares and non-voting preferred shares, will be acquired, it said. A cash consideration of USD 8.2 million will be paid for acquisition of all shares of Aquinox Pharmaceutical, Sun Pharma said.

Devdiscourse | July 29, 2020

Sun Pharma to acquire Canada's Aquinox Pharmaceuticals

Sun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million.

India TV News | July 29, 2020

Sun Pharma to acquire Canada-based Aquinox Pharmaceuticals for $8.2m

Sun Pharmaceutical Industries has announced that one of the fully-owned subsidiaries of Taro Pharmaceutical Industries Ltd is about to to acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 milli…

Nigerian-Canadian News | July 29, 2020

Sun Pharma Gains As US Subsidiary Achieves Resolution On Antitrust Investigations

On Friday, shares of Sun Pharmaceutical Industries Limited rose 4 percent to Rs 497.80 in early trade after its US subsidiary, Taro Pharma reached a settlement agreement with the US Department of Justice (DoJ), Antitrust and Civil divisions to pay $205.7

Goodreturns | July 24, 2020

Sun Pharma's arm Taro resolves all cases with United States Department of Justice

New Delhi: Sun Pharma on Friday said its American arm Taro Pharmaceutical has resolved all cases involving multi-year investigations by US Department of Justice into the country's generic pharmaceutical industry. The US Department of Justice (DOJ) had launched investigations against the company over generic drug pricing. "Taro Pharmaceuticals USA, Inc, has resolved all cases involving the company in connection with the multi-year investigations by the DOJ, Antitrust Division and Civil Division, into the US generic pharmaceutical industry," Sun Pharma said in a regulatory filing. Under a deferred prosecution agreement reached with the DOJ, it said, adding that the department will file an information for conduct that took place between 2013 and 2015. Taro Pharmaceutical said, if the compa...

Economic Times India | July 24, 2020

Taro Pharma settles U.S. price-fixing charges

Taro Pharmaceuticals (TARO) says it agrees to pay ~$205M to settle allegations by the Department of Justice that it conspired to fix prices and rig bids for generic drugs.Under the terms of a three-year deferred prosecution agreement, Taro also agrees to cooperate in the DoJ's ongoing investigation.Taro and other companies...

Seeking Alpha | July 23, 2020

Taro Achieves Global Resolution of DOJ Antitrust Investigations

Taro Achieves Global Resolution of DOJ Antitrust Investigations

Yahoo | July 23, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6071 seconds.